Page 79 - Read Online

Page 12 of 12 Yonemura et al. J Cancer Metastasis Treat 2022;8:43 https://dx.doi.org/10.20517/2394-4722.2022.49

14. Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of
patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005;7:40-6. DOI PubMed
15. Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexad plus gemcitabine as first line chemotherapy for patients with peritoneal
mesothelioma: final report of a phase II tria. J Cin Oncol 2008;26:3567-72. DOI
16. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer
Invest 2003;21:682-9. DOI PubMed
17. Sgarbura O, Gourgou S, Tosi D, et al. MESOTIP: phase II multicenter randomized trial evaluating the association of PIPAC and
systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura
Peritoneum 2019;4:20190010. DOI PubMed PMC
18. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma
(CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530-40. DOI PubMed PMC
19. Tanaka T, Miyamoto Y, Sakai A, Fujimoto N. Nivolumab for malignant peritoneal mesothelioma. BMJ Case Rep 2020;13:e237721.
DOI PubMed PMC
20. White MG, Schulte JJ, Xue L, et al. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or
intraperitoneal chemotherapy. Br J Cancer 2021;124:564-6. DOI
21. Yonemura Y. Reasons why systemic chemotherapy cannot cure patients with cancer. In: Yonemura, Y, editor. Comprehensive
treatment for peritoneal surface malignancy with an intent of cure. Asian School of Peritoneal Surface Oncology: Japanese; 2019. p.
138-139. DOI
22. Dubreuil J, Giammarite F, Rouset P, et al. The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma. Nucl Med Commun
2017;38:312-18. DOI PubMed
23. Laterza R, Kusamura S, Baratti D, et al. Role of explorative laparoscopy to evaluate optimal candicates for cytoreductive surgery and
hyperthermaic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23:187-90. PubMed
24. Baratti D, Kusamura S, Deraco M. Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol
2009;35:1198-9. DOI PubMed
25. Ramp A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC 16 to mesothelin mediated cell adhesion. J
Biol Chem 2004;279:9190-8. DOI
26. Kaya H, Sezgı C, Tanrıkulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
Neoplasma 2014;61:433-8. DOI PubMed
27. Salo SAS, Ilonen I, Laarksonen S, et al. Malignant peritoneal mesothelioma: treatment options and survival. Anticancer Res
2019;39:839-45. DOI PubMed
28. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg
Oncol Clin N Am 2003;12:605-21. DOI PubMed
29. Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive
surgery followed by nyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140-8. DOI PubMed
30. Kepenekian V, Elias D, Passot G, et al. Diffuse naliganat peritoneal mesothelioma: evaluation od systemic chemotherapy with
comprehensive treatment through the RENAPE database multi-institutional retrospective study. Euro J Cancer 2016;65:69-79. DOI
31. Alexander HR, Bartlet DB, Pingpank JF, et al. Treatment factors associated with lon-term survival after cytoreductive surgery snd
regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013;153:779-86. DOI
32. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal
mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686-93. DOI PubMed
33. Yonemura Y, Ishibashi H, Canbay E, et al. Treatment results of diffuse malignant peritoneal mesothelioma. Gan Kagaku Ryoho
2012;39:2416-9. PubMed
34. Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann
Surg Oncol 2014;21:1159-65. DOI PubMed PMC
35. Pavlisko EN, Roggli VL. Sarcomatoid peritoneal mesothelioma: clinicopathologic correlation of 13 cases. Am J Surg Pathol
2015;11:1568-75. DOI PubMed
36. Naffouje S, Tufla KA, Salti GI. The impact of chemotherapy and its timing on survival in malignanrt peritoneal mesothelioma treated
with complete debulking. Med Onco 2018. DOI PubMed
37. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant
peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol
2013;20:1093-100. DOI PubMed
38. Lopock JR. Cellular effects of hyperthermia, relevance to the minimum dose for thermal damage. In J Hyperthermia 2003;19:252-66.
DOI PubMed
39. Yonemura Y. Treatment of peritoneal metastasis from rare diseases: well-differentiated papillary peritoneal mesothelioma. Asian
School of Peritoneal Surface Oncology: Japanese.2019. p.166-7. DOI
40. Le Roy F, Gelli M, Hollebecque A, et al. Conversion to complete cytoreductionsurgery and hyperthermic intraperitoneal chemotherapy
fornmaliganat peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol 2017;24:3640-6. DOI PubMed